What is EIKN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.40B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for EIKN?

P/E (TTM) is n/a and 52-week range is $7.01 to $17.40 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s EIKN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for EIKN?

The company profile lists net income (TTM) near $-547M, EPS (TTM) near $-10.10 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Eikon Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Millbrae, California, US, 54.1M shares outstanding, ISIN US2825641036 when available from company profile and filing metadata.

Chartloom

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Eikon Therapeutics is a biopharmaceutical company. The company is headquartered in Millbrae, California and currently employs 384 full-time employees. The company went IPO on 2026-02-05. The firm has clinical programs at various stages of development, and active discovery efforts in oncology and neurological disease. Its pipeline includes EIK1001 TLR7/8 Melanoma, EIK1001 TLR7/8 NSCLC, EIK1003 PARP1, EIK1004 PARP1, EIK1005 WRN Phase 1, EIK1006, and AR-V7. EIK1001 is a systemically administered dual-agonist of toll-like receptors 7 and 8 that has demonstrated single-agent activity, as well as activity in combination with anti-PD-(L)1 agents, across multiple solid tumor types in Phase 1 trials. EIK1003 targets PARP1, a central component of DNA repair machinery in normal cells. EIK1003 is being evaluated in a Phase 1/2 study of patients with breast, ovarian, or prostate malignancies that have known or suspected deleterious mutations of select homologous recombination repair (HRR) genes.

Employees

384

Website

eikontx.com/

IPO

2026-02-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)